Editor’s Choice. Rosiglitazone: a cautionary taleBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5279 (Published 29 September 2010) Cite this as: BMJ 2010;341:c5279
In this Editor’s Choice by Fiona Godlee, we mixed up some dates in the third paragraph (BMJ 2010;341:c4896, doi:10.1136/bmj.c4896). The UK’s Committee on Human Medicines advised the Medicines and Healthcare Products Regulatory Agency in July (not August, as we stated) that the risks of rosiglitazone outweighed the benefits and that it had no place on the UK market. And, similarly, it was in July (not August) that doctors received a letter suggesting that they seek alternatives to rosiglitazone.
Cite this as: BMJ 2010;341:c5279